CD19 CAR T-cell (CAR-T) therapy is commonly administered to patients with relapsed or refractory large B-cell lymphomas (LBCL), but salvage or bridging therapy can sometimes lead to a complete response (CR) prior to infusion. Limited studies have assessed the outcomes of patients infused in CR. A total of 134 patients with LBCL in CR prior to CAR-T infusion were identified from the CIBMTR registry, with median prior lines of therapy of 3 (range 2–9). At two years post-infusion, the probability of progression-free survival was 43.5% (95% CI 34.4–52.8) and the probability of overall survival was 63.8% (95% CI 54.4–72.6). The cumulative incidence rates of non-relapse mortality and relapse/progression at two years were 9.2% (95% CI 4.5–15.4) and 47.3% (95% CI 38.2–56.6), respectively. The rate of grade 3 or higher cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) were 2.2% and 8.2%, respectively. In summary, CAR-T in heavily pretreated patients with LBCL who are in CR following two or more lines of prior therapy demonstrate that a subset of patients may remain free of progression at two years. Additionally, the toxicity profile was impressive with very low rates of grade 3 CRS and ICANS.

CD19 CAR T 细胞 (CAR-T) 疗法通常用于复发或难治性大 B 细胞淋巴瘤 (LBCL) 患者，但挽救或桥接疗法有时可以在输注前实现完全缓解 (CR)。有限的研究评估了 CR 输注患者的结果。从 CIBMTR 登记中识别出总共 134 名 CAR-T 输注前处于 CR 状态的 LBCL 患者，其中既往治疗线数中位数为 3（范围 2-9）。输注后两年，无进展生存概率为 43.5% (95% CI 34.4–52.8)，总生存概率为 63.8% (95% CI 54.4–72.6)。两年内非复发死亡率和复发/进展的累积发生率分别为 9.2% (95% CI 4.5–15.4) 和 47.3% (95% CI 38.2–56.6)。 3级或以上细胞因子释放综合征（CRS）和免疫效应细胞相关神经毒性综合征（ICANS）的发生率分别为2.2%和8.2%。总之，在接受过两次或两次以上先前治疗后达到 CR 的 LBCL 患者中，CAR-T 表明一部分患者可能在两年内保持无进展。此外，毒性特征令人印象深刻，3 级 CRS 和 ICANS 发生率非常低。